Systemic Medications as Triggers of Acute Angle-Closure Glaucoma: A Narrative Review
Abstract
Background: Acute angle-closure glaucoma (AACG) is an emergency requiring rapid intervention to prevent irreversible optic nerve damage and permanent vision loss. Methods: This narrative review synthesizes the systemic medication classes most implicated in medication-induced AACG, outlining their underlying pathophysiological mechanisms, typical timing of onset, and practical risk-reduction strategies. Evidence was collected through targeted searches of the PubMed, Google Scholar, Cochrane Library, and Web of Science databases, focusing on major review articles, pharmacoepidemiologic studies, and clinical consensus guidelines. Source selection and data synthesis followed a narrative approach without formal risk of bias assessment or meta-analysis. Results: The literature consistently implicates sulfonamide derivatives (mainly topiramate), serotonergic antidepressants and triptans, potent systemic anticholinergics, and adrenergic decongestants. Sulfonamides typically precipitate bilateral, non-pupillary-block AACG via ciliochoroidal effusion, secondary anterior displacement of the lens-iris diaphragm, and an acute myopic shift. Conversely, serotonergic, anticholinergic, and adrenergic agents typically trigger classic pupillary-block AACG in anatomically predisposed eyes with pre-existing narrow angles. Adverse events predominantly occur shortly after treatment initiation or dose escalation. Management relies on prompt medication discontinuation and rapid intraocular pressure…
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.